None
Quote | Almirall Sa Ord (OTCMKTS:LBTSF)
Last: | $9.51 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $9.51 |
High: | $0 |
Low: | $0 |
Volume: | 6 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Almirall Sa Ord (OTCMKTS:LBTSF)
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon re...
2024-03-11 05:53:32 ET Eli Lilly ( NYSE: LLY ) on Sunday reported robust efficacy data from a study for its atopic dermatitis drug, lebrikizumab.... Read the full article on Seeking Alpha For further details see: Eli Lilly eczema drug shows robust efficacy in peo...
Message Board Posts | Almirall Sa Ord (OTCMKTS:LBTSF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon re...
Almirall obtains exclusive global rights to develop and commercialize NN-8828 for use in several fields, including immune inflammatory dermatological diseases NN-8828 is an IL-21 blocker which inhibits the pathophysiological functions induced by this cytokine in several immune-modulated d...
Almirall’s Full-Year 2023 Results Company revenue growth driven by the strong performance of the European Dermatology business (+17% year-on-year) based on key growth divers and new launches: Ilumetri ® growing sales at 33.5% year-on-year; Klisyri ® strong sales g...